TrialJournal of cancer research and clinical oncology2024

Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116).

Dominik Paul Modest et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.